Excluded (notable): Hall 2015 Cell Metab — DEFER (single ward RCT, subsumed by the SR/MA)
Notes: CIM poles already held/staged (Ludwig, Hall-EBM, Ebbeling, Feinman, Hall-UPF); tension near-closure, not a gap. gold-gate: the new item is a high-tier SR/MA.
Excluded (notable): Skinner 2018 GeroScience + Karger strength MA — DEFER (subsumed by the umbrella)
Notes: framed via muscle/function/fracture, NOT T-level. Snyder-2024 = hard-outcome HARM inverting the BMD surrogate (high marginal value). Umbrella also surfaces exercise > T for strength (Layer-1).
Included (FETCHED to inbox): NAMS - Hormone Therapy Position Statement 2022; NICE - Menopause Identification Management NG23 2024; Rossouw - WHI Estrogen Progestin Principal Results 2002. Included (manual): Ambikairajah - Fat Mass Changes Menopause Meta-Analysis 2019
Excluded (notable): Greendale/SWAN 2019 JCI Insight — DEFER (cohort, subsumed by the Ambikairajah MA)
Notes: two independent guidance families (NAMS + NICE) => the guidance-SET null; WHI = the HT hard-outcome RCT. All gold except the body-comp MA (high).
Notes: KEYSTONE GAP (type-G) — no patient-important gold keystone; genuinely mechanism-only, NOT filled with a surrogate substitute. Decision content lives on the visceral-adiposity outcome pages.
Notes: KEYSTONE GAP (type-G) — no gold SR/MA reaching a patient-important outcome via endogenous appetite hormones distinct from Sumithran; NOT filled. Weave as mechanism linking Sumithran <-> GLP-1 <-> adherence.